



NCARD Seminar: Engineering immune cells to target tumour associated antigens

Dr Craig Rive

BC Cancer Agency

Thursday 19 April 2018

2.30 pm

McCusker Auditorium, Harry Perkins

Institute of Medical Research

Dr Craig Rive is a postdoctoral fellow at the BC Cancer Agency in Vancouver, Canada, working in the Genomic Sciences Centre of Professor Rob Holt.

A mechanic by trade, Craig decided after 7 years to return to study as a mature aged student. He received a Bachelor in Science, majoring in Molecular Biology and Biomedical Sciences, and a Bachelor in Forensics, majoring in Forensic Biology and Toxicology, from Murdoch University in 2011. Craig received first class honours in Molecular Biology in 2011, and in 2012 was awarded an Australian Postgraduate Award to begin his PhD studies at the Institute for Immunology and Infectious Disease at Murdoch.

In 2016, while completing his PhD on the immunopathogenesis of drug-induced delayed hypersensitivity reactions, Craig worked as a Research Assistant at the National Centre for Asbestos Related Diseases, helping to develop immune based assays such as Elispot and CD8+ T cell expansion assays.

At the beginning of 2017 Craig received his PhD from Murdoch and moved to Vancouver and his first postdoctoral position at the BC Cancer Agency.



In this seminar, Craig will cover aspects of his research related to the engineering of immune cells to target tumour cells in a immunotherapy approach to cancer treatment. This will include aspects of CAR-T (Chimeric Antigen Receptor) and modified TCR (T cell receptor) research.

After one year in Canada Craig does not want to leave. He is now unfortunately a Canucks fan and has taken to hockey like a duck to water.